Will HIV-prevention drug halt record transmissions?
This week, New Zealand will become one of the first countries in the world to publicly fund the HIV-prevention drug, Pre-Exposure Propylaxis (PrEP). It's part of the New Zealand AIDS Foundation's long-term strategies to end new transmissions by 2025, but will it be effective? Problems are surfacing over its implementation, including questions over exactly who is eligible, and whether doctors are aware of how to correctly prescribe and monitor the drug. Kathryn discusses these points with NZAF Executive Director Jason Myers, and Dr Richard Medlicott, Medical Director, Royal New Zealand College of General Practitioners.